Dipyridamole in the treatment of dengue haemorrhagic fever.
Clinical studies in the treatment of 54 children suffering from DHF with a combination of dipyridamole and ASA as an adjuvant of our standard therapy consisted of fluid, electrolytes, blood, plasma and plasma expanders were evaluated. Heparin was administered in cases of DIC. It appeared that dipyridamole and ASA did not change the mortality significantly, but it prevented the progress of the severity of the disease from grade I and II to grade III and IV.
D000293:Adolescent; D001241:Aspirin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003715:Dengue / Q000188:drug therapy* / Q000401:mortality; D004176:Dipyridamole / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007223:Infant
D004176:Dipyridamole; D006493:Heparin; D001241:Aspirin